



MPE launches a video on Horizon2020 MMPredict - developing a personalised medicines tool for myeloma

There are currently a range of novel and chemotherapy drugs and drug combinations available and in development for the treatment of myeloma. However, as myeloma is a complex and individual cancer, not every treatment is suitable for each patient.

To explore solutions to address this issue, Myeloma Patients Europe (MPE) is participating in **Horizon 2020 MMPredict**.


Funded by the European Commission, this is a multi-stakeholder, pan-European project, aiming to develop a personalised medicine tool to predict the most effective treatment strategy for individual myeloma patients.

To explain the main goals of MMPredict, MPE has filmed a video with some partners working in the project consortium:

- **Erik Valent**, Scientist and Junior Project leader, Skyline DX.
- **Ken Redekop**, PhD Associate Professor, Institute for Medical Technology Assessment, Erasmus Universiteti Rotterdam.
- **Alessandra Laroca**, MD, PhD Consultant Physician of the Division Haematology at the Department of Haematology-Oncology University Hospital Città della Scienza, Torino.



Horizon2020 MMPredict: Exploring predictive treatment approaches in myeloma



For further information, please visit the [Horizon2020 website](#).

You can also find further information on the MPE website [here](#) or the [MPE Q&A on this project](#).

Please email info@mpeurope.org if you have any questions or comments about Horizon2020 MMPredict or other programmes MPE is involved in



Copyright © 2018 Myeloma Patients Europe, All rights reserved.

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#)